Loading viewer...
investor_presentation
Format: PDF investor_presentation
Vivreon Biosciences presents its dual-acting kappa and mu receptor agonist platform with lead candidate in clinical development for pruritus and cough indications. The company highlights statistically significant pruritus reduction data and near-term Phase 2b/3 and Phase 2a topline data expected in H1 2022 for prurigo nodularis and IPF.
investor_presentation
26 Pages
Magyar Telekom
Weatherford International Investor Presentation — July 2022
investor_presentationinvestor_presentation
16 Pages
Weatherford International plc